Safety and efficacy of mirabegron add-on treatment to solifenacin in incontinent OAB subjects with an inadequate response to initial 4-week solifenacin monotherapy

Research Type

Clinical

Abstract Category

Overactive Bladder

Links
	Abstract 490
	Pharmacotherapy for Overactive Bladder Scientific Podium Short Oral Session 34
	Friday 9th October 2015
	09:22 - 09:30
	515ABC
	Detrusor Overactivity Incontinence Overactive Bladder
	1. Bristol Urological Institute, Bristol, UK, 2. Dokuz Eylül University, Izmir, Turkey, 3. University of Athens,"Alexandra" Hospital, Athens, Greece, 4. Astellas Pharma Europe Ltd, Chertsey, Surrey, UK, 5. Astellas Pharma Global Development, Leiden, Netherlands, 6. Alliance Urology Specialists, Greensboro, NC, USA
Presenter
S Scott MacDiarmid
Abstract PDF Disclosure PDF Edit Abstract Abstract Centre